23 Stock Top Picks and 7 ETF (Nov 30 Dec 6)

He sold covered calls on Wednesday to ride high volatility. He did it to add some hedging as well as cash flow.

They delivered a good quarter a few weeks ago. Long-term secular growth lies ahead.

Add for long-term income? Includes telcos likes BCE, Telus, and Rogers, as well as utilities. Still likes it a lot, has it in his global dividend strategy. He reduced exposure on recent rally, moving to ZPAY for the lower risk. Before adding, wait for it to hit the low $10s.He feels that interest rate pressure…

Good if interest rates rise. Not when rates are falling. Would not invest lately (Fed likely to cut rates). 

High-dividend ETF, with a low MER. For US names. VIG is in USD, VGG uses CAD. Names like AAPL, AVGO, JPM, MSFT and so on. More of a tilt of rising dividends, especially important when interest rates are rising.

(A Top Pick Nov 10/23, Up 4%) Will continue to hold. Likes direction of chart. Consumer staples do well regardless of direction of economy. Believes still upside left in stock. 

Above $35, has sold all exposure to AMLP. Closer to $30, it is a good place to enter for a trade. Probably will do well buying dips and selling rallies in the near term. Maximum upside is probably $40. Long term, there are some challenges.

It's all about interest rates. Probably we need to see the 30-year fall below 6.0% to trigger pent-up demand and will likely get it. We're 5 million homes short in the U.S. and have been underproducing for 14 years.

Making RSI new lows versus the market. Avoid this whole neighbourhood for a while.

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research BNS continues to pay a solid dividend yield of 5.4%, and it is up 22% on a year-to-date basis, and 29% on a one-year basis. Its earnings outlook is improving, and most analyst estimates are trending higher recently. Analysts have been upping their price targets…

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research EPS of 68c missed estimates of 67c; Insurance revenue was $807.6M. Revenue rose 10.5%. ROE was 18.6%, higher than estimates (18.5%). Book value rose to $15.64 from $12.58. Debt to capital 11.6%, better than estimates (11.7%). The company noted strength in Trisura Specialty  and growing…

Not a good investment for short term speculation.Is very hard to time market for traders.Good for long term holders.

Would prefer over TD bank. Excellent business that is rock sold. Very strong balance sheet. Excellent brand name in Canada. 

(A Top Pick Sep 06/23, Up 89%) House insurance always goes up and it is the best in its field with little competition. Trades at 11X earnings.

The market has punished it too much. It is in the residential rental sector in the U.S., especially in the sun belt. The rentals are affordable and appeal especially to the 35 to 44 year old demographic who want to rent good homes rather than buy. The share price is at a 40% discount to…

(A Top Pick Dec 05/18, Up 45%) It's a Blackstone-sponsored company that bought a bunch of single-family homes and rent them out. Blackstone IPO'd this and sold it in tranches over time. Now, the stock has legs and doesn't need the parent's support. They rent to tenants and are adding ancillary businesses, like pet services…

The largest US office REIT. Used to own it, still likes it alot for owning specialized spaces, like labs for biotechs. But this niche has problems, lacking IPOs and new companies. Is down 20% YTD.

He does not own this one, despite the earnings metrics looking solid and there is no net debt. They missed on a recent quarterly earning, but not a bid deal. They are trading at 7 times cash flow and 7 times EBITDA. He would like to see the ROE improve a bit. Price momentum has…

Kudos to the new executive at delevering and cleaning things up. Inexpensive valuation. Still a lot of debt. A turnaround story. 3% of your portfolio is a bit heavy. Add some diversity. Had a great move. Be cautious.

They report Tuesday. Are the only health insurer that regularly beats earnings. Good risk/reward.

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

Pharma companies are always facing the patent wall, needing to spend R&D to innovate new drugs. Very difficult to predict the next blockbuster. He prefers and owns JNJ and ABT, more diversified.

He sold. Problems with CPAP machines, have since been settled. Slow growth, struggling on a number of fronts. Still in restructuring mode. Look elsewhere.

Excellent company with strong pipeline of new projects. Valuation has seen a new low which makes a good time to buy. Vaccine hesitation in new Trump administration not a concern. Dividend very safe - provides margin for investors. 

Concerns regarding tariffs on components and whether Trump will expand public transit. Making progress on debt, but it's still too high. Supply chain issues. Too many questions to step in:  growth, costs, debt.

(A Top Pick Sep 25/23, Down 37%) They remain the leader in nuclear valves. Shockingly, the French government blocked an American company from buying this small Montreal company. So, the family decided to sell the company and he expects it will be at a higher price. Their backlog and margins are growing. He still owns…

(A Top Pick Jun 02/20, Up 26%) A Japanese company, a leader in test equipment. They are incredibly well positioned without a lot of competition. A global leader. They have zero debt.

It is an interesting business. It is specialty pharmacies. They do medication for long term care facilities. They have an interesting pouch technology. They had quite a significant debt load and made a big dent in it when they sold their surgical business. They are trying to pick up new contracts. He has owned it…

Very strong business - founder led & owned. Exception creator of wealth the past ~20 years. Has owned shares since 2014. Very good consolidator of convenience stores. High quality capital allocation skills. Recent 7-Eleven M&A is interesting, but depends on the final price that is settled on. Would recommend holding and/or buying. 

SU vs. CNQ He doesn't generally participate in the E&P space, as it's hard to make decisions based on the underlying commodity price. Bigger picture, still huge demand for Canadian oil and gas on world markets. EVs won't take over anytime soon.SU had been an underperformer and a laggard. Management changes have resulted in turning…